Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XingpiJieyu Formula + escitalopram
- Development stage
- Unknown
- Lead developer
- Peking University Sixth Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
XingpiJieyu Formula combined with escitalopram is an investigational combination therapy being studied by Peking University Sixth Hospital for the treatment of severe major depressive disorder (MDD). This treatment specifically targets patients classified with a Liver-Stagnation and Spleen-Deficiency pattern according to Traditional Chinese Medicine (TCM). The combination consists of escitalopram, a selective serotonin reuptake inhibitor (SSRI) small molecule, and XingpiJieyu Formula (XPJYF), a multi-component herbal preparation. XPJYF is intended as an adjunctive therapy to enhance the antidepressant efficacy of escitalopram and potentially reduce side effects. Its mechanism of action involves modulation of the gut microbiota-brain axis, the cAMP-PKA-CREB-BDNF signaling pathway, and mitochondrial energy metabolism. The combination is currently being evaluated in a Phase 4 clinical trial to assess its impact on clinical symptoms and biological markers such as EEG patterns and mitochondrial biosynthesis.
- Other names
- Xingpi Jieyu FormulaXing-Pi Jie-YuXPJYF + escitalopram
02
Targets
SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on XingpiJieyu Formula + escitalopram.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XingpiJieyu Formula + escitalopram.